Search Results evaluable patients
1.
Genmab Announces Data on All Evaluable Patients in HuMax(R)-CD20 NHL Phase I/II Study.
...non-Hodgkin's lymphoma (NHL). Overall, there were 37 evaluable patients and objective response rates at each dose level...followed for 12 months. Thirty-seven patients were evaluable. Patients in this study had relapsed or refractory follicular...
December 1, 2005; PR Newswire
2.
Clinical Data on REVIMID(TM) in Relapsed or Refractory Multiple Myeloma Presented at the American Society of Hematology 45th Annual Meeting; * 91 Percent of Evaluable Patients Achieved Stabilization of Disease or Better in Relapsed/Refractory Myeloma.
...Richardson reported that 73 of 91 evaluable patients (80 percent) with progressive...after eight weeks. Five of 83 evaluable patients (6) achieved a complete paraprotein...progressive disease. Of the 42 evaluable patients with relapsed disease, 3 (7...
December 9, 2003; PR Newswire
3.
NCI Study With Delcath Cancer Technology Reports Significant Anti-Tumor Activity; 60 Percent of Evaluable Patients Responded to High Dose Therapy Aimed Directly at Tumor.
...response rate in patients with primary ocular melanoma was higher, with anti-tumor activity observed in 80 percent of evaluable patients. The NCI study was conducted to determine the optimal dose of the widely prescribed cancer drug melphalan using...
January 26, 2004; PR Newswire
4.
New REVIMID(TM) Clinical Data Shows Potential as Novel Approach to Treating Myelodysplastic Syndromes (MDS); -- Red Blood Cell Production Restored in 64 Percent of Evaluable Patients.
...with MDS, targeting the cause of the condition rather than simply managing its symptoms. In the study, 16 of 25 evaluable patients (64 percent) experienced an erythroid response to REVIMID treatment that was defined by at least a 50 percent decrease...
May 15, 2003; PR Newswire
5.
Additional Clinical Data Presented on REVIMID(TM) in Myelodysplastic Syndromes At the American Society of Hematology 45th Annual Meeting; * Red Blood Cell Production Restored in 67 Percent of Evaluable Patients.
...patients were enrolled, and 36 are evaluable for response after completing 8 or more weeks of therapy. Twenty-four evaluable patients (67 percent) experienced an erythroid response to REVIMID treatment that was defined by at least a 50 percent decrease...
December 8, 2003; PR Newswire
6.
Clinical Data on ACTIMID(TM) in Multiple Myeloma at The American Society of Hematology 45th Annual Meeting; 93 of Evaluable Patients Achieved Stabilization of Disease or Better in Relapsed/Refractory Myeloma.
Celgene Corporation announced today that data evaluating clinical results on ACTIMID (CC-4047) as a therapeutic approach for patients with relapsed/refractory multiple myeloma was presented at the American Association of Hematology 45th Annual Meeting in San Diego, one of the world's largest
December 9, 2003; PR Newswire
7.
Thalomid(R) Phase I/II Clinical Data Presented as Combination Therapy For Treating Prostate Cancer; 76 of evaluable patients demonstrated prostate-specific antigen response in second line therapy.
Celgene Corporation announced today the results of data presented at the European Cancer Conference (ECCO) in Copenhagen, Denmark which used THALOMID(R) in combination with chemotherapy androgen-independent prostate carcinoma (AIPCa). The Phase I/II study results demonstrated that 18 of 33 (55)
September 25, 2003; PR Newswire
8.
Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial.
29% of First 65 Evaluable Patients Experienced Either a Complete...percent (n=19) of the first 65 evaluable patients enrolled in the trial experienced...percent (n=29) of the first 65 evaluable patients experienced either a complete...
May 15, 2008; Business Wire
9.
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study.
- 50% of All Evaluable Patients in Phase I Study Receiving Combination...or Stable Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast...I data indicated that half of evaluable patients in the trial achieved objective...
June 2, 2008; PR Newswire
10.
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer.
...benefit observed in over 60% of evaluable patients - SEOUL, South Korea, Sept...cycles. To date, over 60% of evaluable patients in the phase 2 study have had...untreated NSCLC: >60% of evaluable patients experienced clinical benefit...
September 5, 2007; PR Newswire
|
